LEADER 05272nam 2201585z- 450 001 9910367743903321 005 20231214133452.0 010 $a3-03921-655-4 035 $a(CKB)4100000010106278 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/56155 035 $a(EXLCZ)994100000010106278 100 $a20202102d2019 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPheochromocytoma (PHEO) and Paraganglioma (PGL) 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 215 $a1 electronic resource (380 p.) 311 $a3-03921-654-6 330 $aThis book outlines some new advances in genetics, clinical evaluation, localization, therapy (newly including immunotherapy) of pheochromocytoma and paraganglioma including their metastatic counterparts. Well-known and experienced clinicians and scientists contributed to this book to include some novel approaches to these tumors. This book will serve to various health care professionals from different subspecialties, but mainly oncologists, endocrinologists, endocrine surgeons, pediatricians, and radiologists. This book shows that the field of pheochromocytoma/paraganglioma is evolving and a significant progress has been made in last 5 years requiring that health care professionals and scientists will learns new information and implement it in their clinical practice or scientific work, respectively. This book should not be missed by anybody who is focusing on neuroendocrine tumors, their newest evaluation and treatment. 517 $aPheochromocytoma 610 $apolycythemia 610 $apeptide receptor radiotherapy 610 $avasculogenesis 610 $acatecholamines 610 $aneuroendocrine 610 $aGTV 610 $aadaptive immunity 610 $atherapy resistance 610 $ahistology 610 $atransgenic mice 610 $acryoablation 610 $aspheroids 610 $aenergy metabolism 610 $asomatostatinoma 610 $aangiogenesis 610 $apheochromocytoma 610 $aSDHD 610 $apercutaneous ethanol injection 610 $ametanephrines 610 $aSDHB 610 $aglobal longitudinal strain 610 $amutation 610 $anormetanephrines 610 $acatecholamine 610 $aPASS 610 $aPGL 610 $a177Lu-DOTATATE 610 $achromosomal alteration 610 $aspeckle-tracking echocardiography 610 $alL-6 610 $adog 610 $apercutaneous ablation 610 $astem-like tumor cells 610 $aEPAS1 610 $aneural crest 610 $afluorescence imaging 610 $aneutrophil 610 $axenograft 610 $ainflammation 610 $ahead and neck 610 $aweighted standard deviation 610 $aFGF21 610 $acalorimetry 610 $aHIF 610 $aaverage real variability 610 $anext-generation sequencing 610 $aadrenocortical carcinoma 610 $acarotid body 610 $ahypoxia-inducible factor 610 $aparaganglioma 610 $asuccinate dehydrogenase 610 $ablood pressure variability 610 $aarrhythmia 610 $amortality 610 $aNF1 610 $atoll-like receptor 610 $aGAPP 610 $aNET 610 $asubclinical systolic dysfunction 610 $apheochromocytoma and paraganglioma 610 $aPET-CT 610 $apan-cancer analysis 610 $amouse pheochromocytoma cells 610 $ainnate immunity 610 $aneurogenesis 610 $aneuroendocrine tumor 610 $aobesity 610 $ahypotension 610 $ahypoxia 610 $aCNV detection 610 $a18F-FDOPA 610 $acomparative genomics 610 $aadrenomedullary function 610 $aPCC 610 $apathogen-associated molecular patterns 610 $aadrenal tumor 610 $aradiotherapy 610 $a11C-hydroxy-ephedrine 610 $aradiofrequency ablation 610 $aPPGL 610 $aminimally invasive procedure 610 $asporadic 610 $adiabetes mellitus 610 $aadrenal incidentaloma 610 $agermline mutation 610 $aimmunotherapy 610 $aVHL 610 $aimmunohistochemistry 610 $ametastatic OR malignant pheochromocytoma 610 $aerythropoietin 610 $apostoperative 610 $atargeted therapy 610 $aPRRT 610 $ametastatic 610 $amitochondria 610 $aT cell 610 $aTCA cycle 610 $ameta-analysis 610 $apseudohypoxia 610 $aectopic secretion 610 $aradiosensitization 610 $achromogranin A 610 $ahereditary 610 $ahypertension 610 $aPET 610 $aphosphorylation tyrosine hydroxylase 700 $aPacak$b Karel$4auth$0881323 702 $aTai?eb$b David$4auth 906 $aBOOK 912 $a9910367743903321 996 $aPheochromocytoma (PHEO) and Paraganglioma (PGL)$93030537 997 $aUNINA